Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma + minoxidil is a combination therapy being investigated by Indonesia University for the treatment of male androgenetic alopecia. Platelet-rich plasma (PRP) is an autologous preparation of concentrated platelets that, upon activation, releases various growth factors including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor beta (TGF-β). These factors stimulate the proliferation of dermal papilla cells and enhance local vascularization. Minoxidil, a small molecule vasodilator, acts as an ATP-sensitive potassium channel opener, which is thought to widen blood vessels and open potassium channels, allowing more oxygen, blood, and nutrients to reach the hair follicles. The combination aims to provide synergistic effects by combining the regenerative properties of PRP with the established hair-growth-promoting effects of topical minoxidil.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma + minoxidil.